Sentinel lymph node biopsy (SLNB) represents the standard axillary staging procedure for patients with clinically node-negative breast cancer. Whereas SLNB has been demonstrated to be reliable and to reduce axillary staging morbidity compared to standard axillary lymph node dissection (ALND), there is uncertainty as to how to optimize axillary staging in the context of primary systemic therapy (PST) and minimize the morbidity of ALND in case of positive SLNB.
|Translated title of the contribution||Axillary staging in patients with breast cancer. Before or after neoadjuvant chemotherapy?|
|Number of pages||8|
|Publication status||Published - 2016|